Rapacuronium bromide

Rapacuronium bromide
Rapacuronium bromide
Clinical data
Other names[(2S, 3S, 5S, 8R, 9S, 10S, 13S, 14S, 16S, 17S)-3-acetyloxy-10,13-dimethyl-2-(1-piperidyl)-16-(1-prop-2-enyl-3,4,5,6-tetrahydro-2H-pyridin-1-yl)-2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,11 ,12 ,14, 15, 16, 17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]propanoate
Routes of
administration
Intravenous
ATC code
  • none
Legal status
Legal status
  • US: Withdrawn
Pharmacokinetic data
BioavailabilityNot applicable
Protein bindingVariable
MetabolismHydrolyzed to active metabolites
CYP system not involved
Elimination half-life141 minutes (mean)
ExcretionRenal and fecal
Identifiers
IUPAC name
  • (2β,3α,5α,16β,17β)-3-(acetyloxy)-16-(1-allylpiperidinium-1-yl)-2-piperidin-1-yl-17-(propionyloxy)androstane bromide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.211.226
Edit this at Wikidata
Chemical and physical data
FormulaC37H61N2O4+
Molar mass597.905 g·mol−1
3D model (JSmol)
SMILES
  • [Br-].O=C(O[C@H]6[C@@H]([N+]1(C\C=C)CCCCC1)C[C@@H]5[C@]6(C)CC[C@H]3[C@H]5CC[C@H]4C[C@H](OC(=O)C)[C@@H](N2CCCCC2)C[C@]34C)CC
InChI
  • InChI=1S/C37H61N2O4.BrH/c1-6-20-39(21-12-9-13-22-39)32-24-30-28-15-14-27-23-33(42-26(3)40)31(38-18-10-8-11-19-38)25-37(27,5)29(28)16-17-36(30,4)35(32)43-34(41)7-2;/h6,27-33,35H,1,7-25H2,2-5H3;1H/q+1;/p-1/t27-,28+,29-,30-,31-,32-,33-,35-,36-,37-;/m0./s1 checkY
  • Key:LVQTUXZKLGXYIU-GWSNJHLMSA-M checkY
 ☒NcheckY (what is this?)  (verify)

Rapacuronium bromide (brand name Raplon) is a rapidly acting, non-depolarizing aminosteroid neuromuscular blocker formerly used in modern anaesthesia, to aid and enable endotracheal intubation, which is often necessary to assist in the controlled ventilation of unconscious patients during surgery and sometimes in intensive care. As a non-depolarizing agent it did not cause initial stimulation of muscles before weakening them.

Due to risk of fatal bronchospasm it was withdrawn from the United States market by Organon on March 27, 2001, less than 2 years after its FDA approval in 1999.[1]

References

  1. Shapse, Deborah (March 27, 2001). "Voluntary Market Withdrawal" (PDF). (10.8 KiB). Organon International. Retrieved on 2007-04-02.


This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.